ANTH Key Stats
- Anthera Pharmaceuticals Management Discusses Q1 2013 Results - Earnings Call Tra... May 20
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financ... May 17
- Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results PR Newswire May 13
- ANTHERA PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 13
- Q1 2013 ANTHERA PHARMACEUTICALS INC Earnings Release - After Market Close May 13
- Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibi... May 7
- Anthera Announces First Quarter 2013 Financial Report and Conference Call PR Newswire May 3
- Anthera Pharma (ANTH) Files $100M Mixed Shelf Street Insider Apr 8
- Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secure... Apr 5
- ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive... Apr 5
ANTH Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Anthera Pharmaceuticals is down 68.59% over the last year vs S&P 500 Total Return up 27.77%, GlaxoSmithKline up 25.97%, and Pfizer up 35.86%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ANTH
Pro Report PDF for ANTH
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ANTH Pro Report PDF
Pro Strategies Featuring ANTH
Did Anthera Pharmaceuticals make it into our Pro Portfolio Strategies?